Hanmi Pharm's neutropenia drug launched in USA

[Source: Hanmi Pharmaceutical]

South Korea’s Hanmi Pharmaceutical has a chance to crack $2 trillion U.S. market for the treatment of neutropenia with a commercial launch of medicine Rolvedon (eflapegrastim-xnst) through its American partner.

Spectrum Pharmaceuticals, the U.S. marketing authorization holder of the drug, launched the drug developed by Hanmi across the U.S., the Korean pharmaceutical company said on Sunday.

The FDA-approved Rolvedon, also known as Rolontis in Korea, is a long-acting granulocyte-colony stimulating factor for the treatment and prevention of chemotherapy-induced neutropenia. Hanmi developed the drug with its proprietary LAPSCOVERY (Long-Acting Protein/Peptide Discovery) technology.

Neutropenia occurs when the body has fewer neutrophils, a type of white blood cell that plays an important role in innate immunity.

The medicine is the first drug cleared by the FDA among Hanmi’s pipeline assets and is produced at a factory in Pyeongtaek, Gyeonggi, which recently passed the FDA’s inspection.

Hanmi Pharmaceutical shares remained in positive territory on Monday after the day’s high of 252,000 won, up 3.70 percent in the early trade.

[ⓒ Maeil Business Newspaper & mk.co.kr, All rights reserved]